Overview
Compare with Glucotrack, Inc., Bluejay Diagnostics, Inc. or QTREX Quantum Ltd., or pick any stock.
- TickerFOFA on OTC1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersCentennial, Colorado1
- Incorporated inNV2
- Business address6898 S. University Blvd.,, Suite 100, Centennial, Co 801222
- Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
See how the biggest companies compare on our leaderboards
June 28, 2021, the Company entered into a Share Exchange Agreement (“Exchange Agreement”) by and among mPathix Health, Inc.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Other costs100¢$221.8K
Out of $221.8K in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net revenue | $221.8K | |
| Gross Profit | $221.8K | |
| Marketing expenses | $2.0K | |
| Warrants issued for services | $67.2K | |
| Stock based compensation - related parties | $137.3K | |
| General and administrative | $516.4K | $96.5K |
| Total operating expenses | $722.8K | $96.5K |
| Loss from operations | -$501.1K | -$96.5K |
| Interest expense | $5.7K | $4.0K |
| Other income | -$14.0K | |
| Total other (income) expenses | -$8.3K | $4.0K |
| Loss before income taxes | -$492.7K | -$100.5K |
| Net loss | -$492.7K | -$100.5K |
| Net loss per share, basic | -$0.02 | $0.00 |
| Net loss per share, diluted | -$0.02 | $0.00 |
| Basic | 26.7M shares | 20.3M shares |
| Diluted | 26.7M shares | 20.3M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2025-07-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash | $155.8K | $13.6K | ||
| Accounts receivable | $74.8K | |||
| Other current assets | $39.8K | $7.0K | ||
| Total current assets | $270.4K | $20.6K | ||
| Intangible assets, net | $437.1K | |||
| Goodwill | $835.6K | |||
| Total assets | $1.5M | $20.6K | ||
| Accounts payable and accrued expenses | $578.5K | $33.3K | ||
| Short-term note payable | $9.6K | |||
| Other current liabilities | $1.1K | |||
| Total current liabilities | $578.5K | $44.0K | ||
| Long term note | $300.0K | |||
| Total long-term liabilities | $300.0K | |||
| Total liabilities | $878.5K | $44.0K | ||
| Common stock, $0.001 par value, 750,000,000 shares authorized; 30,202,004 and 20,439,950 shares issued and outstanding at December 31, 2025 and 2024, respectively | $30.2K | $20.4K | ||
| Additional paid-in-capital | $5.7M | $4.5M | ||
| Accumulated deficit | -$5.0M | -$4.5M | ||
| Total stockholders equity (deficit) | $664.5K | -$23.4K | -$523.0K | |
| Total liabilities and stockholders equity (deficit) | $1.5M | $20.6K | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 25.0M shares | 25.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 750.0M shares | 750.0M shares | ||
| Common stock, shares issued | 30.2M shares | 112.1K shares | 20.4M shares | |
| Common stock, shares outstanding | 30.2M shares | 20.4M shares |
| Period ending | 2025-12-31 | 2025-07-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash | $155.8K | $13.6K | ||
| Accounts receivable | $74.8K | |||
| Other current assets | $39.8K | $7.0K | ||
| Total current assets | $270.4K | $20.6K | ||
| Intangible assets, net | $437.1K | |||
| Goodwill | $835.6K | |||
| Total assets | $1.5M | $20.6K | ||
| Accounts payable and accrued expenses | $578.5K | $33.3K | ||
| Short-term note payable | $9.6K | |||
| Other current liabilities | $1.1K | |||
| Total current liabilities | $578.5K | $44.0K | ||
| Long term note | $300.0K | |||
| Total long-term liabilities | $300.0K | |||
| Total liabilities | $878.5K | $44.0K | ||
| Common stock, $0.001 par value, 750,000,000 shares authorized; 30,202,004 and 20,439,950 shares issued and outstanding at December 31, 2025 and 2024, respectively | $30.2K | $20.4K | ||
| Additional paid-in-capital | $5.7M | $4.5M | ||
| Accumulated deficit | -$5.0M | -$4.5M | ||
| Total stockholders equity (deficit) | $664.5K | -$23.4K | -$523.0K | |
| Total liabilities and stockholders equity (deficit) | $1.5M | $20.6K | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 25.0M shares | 25.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 750.0M shares | 750.0M shares | ||
| Common stock, shares issued | 30.2M shares | 112.1K shares | 20.4M shares | |
| Common stock, shares outstanding | 30.2M shares | 20.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$492.7K | -$100.5K |
| Amortization expense | $37.9K | |
| Warrants issued for services | $67.2K | |
| Stock based compensation - related parties | $137.3K | |
| Accounts receivable | -$74.8K | |
| Other current assets | -$32.8K | -$7.0K |
| Accounts payable and accrued expenses | $95.2K | $17.1K |
| Other current liabilities | $528 | $1.1K |
| Net cash used in operating activities | -$262.2K | -$89.4K |
| Acquisition of intangible assets | -$560.6K | |
| Net cash used in investing activities | -$560.6K | |
| Advance from shareholder | $525 | |
| Issuance of common stock for cash | $965.0K | $100.0K |
| Net cash provided by financing activities | $965.0K | $100.5K |
| Net increase in cash | $142.2K | $11.2K |
| Common stock issued for conversion of short-term note payable and accrued interest | $11.2K | |
| Common stock issued in conjunction with share agreement | $500.0K |
No quarter-by-quarter statement was filed.
What it owns
What FAMILY OFFICE OF AMERICA, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $835.6K4 Dec 31, 2025 | ||
| Intangible assets, net (excluding goodwill) | $437.1K4 Dec 31, 2025 | ||
| Accumulated amortization | -$37.9K4 Dec 31, 2025 | $966.8K5 Dec 31, 2021 | −103.9% |
| Finite-lived intangibles, net | $437.1K4 Dec 31, 2025 |
Properties, in its own words
The Company has an office located at 6898 S. University Blvd., Suite 100, Centennial, Colorado 80122 with telephone number: (303) 874-7487. As of the date of this filing, the Company does not have any physical property other than its prototype medical device equipment.
Item 2 of the 10-K filed Apr 16, 2026.3
Former names
- Qualis Innovations, Inc.Nov 12, 2021 to Nov 12, 20242
Timeline
Filings
45 filings to the SEC since October 2021: 5 annual reports, 13 quarterly reports, 5 major events, 22 other. The latest 20:
- Aug 14, 202610-Q EDGAR
- May 15, 202610-Q EDGAR
- Apr 16, 202610-K EDGAR
- Apr 1, 2026NT 10-K EDGAR
- Nov 14, 202510-Q EDGAR
- Oct 8, 20258-K EDGAR
- Aug 13, 202510-Q EDGAR
- May 15, 202510-Q EDGAR
- Mar 10, 202510-K EDGAR
- Nov 12, 202410-Q EDGAR
- Aug 12, 202410-Q EDGAR
- Jul 18, 202410-K/A EDGAR
- Jul 18, 2024UPLOAD EDGAR
- Jul 17, 2024CORRESP EDGAR
- Jul 15, 20248-K EDGAR
- Jul 8, 2024UPLOAD EDGAR
- May 14, 202410-Q EDGAR
- Apr 11, 202410-K EDGAR
- Apr 3, 2024NT 10-K EDGAR
- Nov 20, 202310-Q EDGAR
The 45 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How FAMILY OFFICE OF AMERICA, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARFAMILY OFFICE OF AMERICA, INC.1
- CIK0001871181
- Employer ID (EIN)84-24884983
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company3
- Incorporated inNevada3
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address6898 S. University Blvd.,, Suite 100, Centennial, CO 801221
- Phone303-874-74741
- Shares outstanding30,826,004 as of Aug 14, 20269
- Public float$5.9M as of Jun 30, 20253
- AuditorVictor Mokuolu, CPA PLLC, Houston, Texas PCAOB ID 6771; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceNov 12, 20211
- Filings45 in all: 10-Q (13), CORRESP (6), 8-K (5), UPLOAD (5), 10-K (4), S-1/A (4), NT 10-K (3), NT 10-Q (2)1
All 11 form types
10-K/A (1), EFFECT (1), S-1 (1)
- Latest filingsAnnual report (10-K) Apr 16, 2026
Quarterly report (10-Q) Aug 14, 2026
Latest 8-K (8-K) Oct 8, 2025
Risk factors and legal proceedings
Legal proceedings
From time to time, we may become party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our business. We are not currently involved in legal proceedings that could reasonably be expected to have a material adverse effect on our business, prospects, financial condition or results of operations. We may become involved in material legal proceedings in the future. To the best our knowledge, none of our directors, officers or affiliates is involved in a legal proceeding adverse to our business or has a material interest adverse to our business.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARChange of auditor
- 12SEC EDGARExecutive or director change
- 13SEC EDGARExecutive or director change
- 14SEC EDGARExecutive or director change